Barclays analyst Etzer Darout downgraded Tvardi Therapeutics Inc (NASDAQ: TVRD) from Equalweight to Underweight with a price target of $3.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE